The DOI matches its Crossref record; 512 of the 512 references it cites were found in a registry or an index.
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
Open accessAbstract
Acetylcholinesterase (AChE) plays an important role in the pathogenesis of neurodegenerative diseases by influencing the inflammatory response, apoptosis, oxidative stress and aggregation of pathological proteins. There is a search for new compounds that can prevent the occurrence of neurodegenerative diseases and slow down their course. The aim of this review is to present the role of AChE in the pathomechanism of neurodegenerative diseases. In addition, this review aims to reveal the benefits of using AChE inhibitors to treat these diseases. The selected new AChE inhibitors were also assessed in terms of their potential use in the described disease entities. Designing and searching for new drugs targeting AChE may in the future allow the discovery of therapies that will be effective in the treatment of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
Muhammad, T., Ikram, M., Ullah, R., Rehman, S., & Kim, M. (2019) · Nutrients · doi:10.3390/nu11030648 · Cited by 443
RetractedMenze, E. T., Esmat, A., Tadros, M. G., Abdel‐Naim, A. B., & Khalifa, A. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117223 · Cited by 84
RetractedMani, S., Sekar, S., Barathidasan, R., Manivasagam, T., Thenmozhi, A. J., Sevanan, M., Chidambaram, S. B., Essa, M. M., Guillemin, G. J., & Sakharkar, M. K. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9869-3 · Cited by 79
RetractedArdah, M. T., Ghanem, S. S., Abdulla, S. A., Lv, G., Emara, M. M., Paleologou, K. E., Vaikath, N. N., Lu, J., Li, M., Vekrellis, K., et al. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-2849-1 · Cited by 34
RetractedHampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.08.016 · Cited by 25
RetractedNeurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“β-amyloid (βA) has a neurotoxic effect on mature neurons, leading to their death [51].”
BackgroundThe cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.71 · Cited by 1,414
van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & van den Berg, L. H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31287-4 · Cited by 1,298
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Inestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,101
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
The changing scene of amyotrophic lateral sclerosis
Robberecht, W., & Philips, T. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3430 · Cited by 957
Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P. H., Silman, I., & Sussman, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9031 · Cited by 899
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Pharmacological properties of Salvia officinalis and its components
Ghorbani, A., & Esmaeilizadeh, M. (2017) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2016.12.014 · Cited by 677
Clinical diagnosis and management of amyotrophic lateral sclerosis
Hardiman, O., van den Berg, L. H., & Kiernan, M. C. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.153 · Cited by 621
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
The cholinergic system and Parkinson disease
Bohnen, N. I., & Albin, R. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.048 · Cited by 566
Bohnen, N. I., Kaufer, D. I., Ivanco, L. S., Lopresti, B., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 551
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Epidemiology of multiple sclerosis
Leray, E., Moreau, T., Fromont, A., & Edan, G. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.006 · Cited by 478 · cited 1×
“Women tend to develop SM twice as often as men [140].”
BackgroundMicroglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
Pavlov, V. A., Parrish, W. R., Rosas-Ballina, M., Ochani, M., Puerta, M., Ochani, K., Chavan, S., Al-Abed, Y., & Tracey, K. J. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.06.011 · Cited by 435
Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis
Maniatis, S., Äijö, T., Vickovic, S., Braine, C., Kang, K., Mollbrink, A., Fagegaltier, D., Andrusivová, Ž., Saarenpää, S., Saiz-Castro, G., et al. (2019) · Science · doi:10.1126/science.aav9776 · Cited by 429
A Structural Motif of Acetylcholinesterase That Promotes Amyloid β-Peptide Fibril Formation
De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., & Inestrosa, N. C. (2001) · Biochemistry · doi:10.1021/bi0101392 · Cited by 413
History of falls in Parkinson disease is associated with reduced cholinergic activity
Bohnen, N. I., Müller, M. L. T. M., Koeppe, R. A., Studenski, S. A., Kilbourn, M. A., Frey, K. A., & Albin, R. L. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1ded6 · Cited by 409
Winblad, B., Kilander, L., Eriksson, S., Minthon, L., Båtsman, S., Wetterholm, A.-L., Jansson-Blixt, C., & Haglund, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68350-5 · Cited by 388
Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways
Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Heiss, W. D. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 384
Galantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Perry, N. S. L., Bollen, C., Perry, E. K., & Ballard, C. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(03)00108-4 · Cited by 383
Mineur, Y. S., Obayemi, A., Wigestrand, M. B., Fote, G. M., Calarco, C. A., Li, A. M., & Picciotto, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219731110 · Cited by 375
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET
Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ab2b58 · Cited by 366
Karussis, D. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.022 · Cited by 366
MicroRNA-132 Potentiates Cholinergic Anti-Inflammatory Signaling by Targeting Acetylcholinesterase
Shaked, I., Meerson, A., Wolf, Y., Avni, R., Greenberg, D., Gilboa-Geffen, A., & Soreq, H. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.019 · Cited by 366
Structural roles of acetylcholinesterase variants in biology and pathology
Grisaru, D., Sternfeld, M., Eldor, A., Glick, D., & Soreq, H. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00693.x · Cited by 355
Ordentlich, A., Barak, D., Kronman, C., Flashner, Y., Leitner, M., Segall, Y., Ariel, N., Cohen, S., Velan, B., & Shafferman, A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85305-x · Cited by 348
Akhondzadeh, S., Noroozian, M., Mohammadi, M., Ohadinia, S., Jamshidi, A. H., & Khani, M. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00463.x · Cited by 344
Induction of acetylcholinesterase expression during apoptosis in various cell types
Zhang, X. J., Yang, L., Zhao, Q., Caen, J. P., He, H. Y., Jin, Q. H., Guo, L. H., Alemany, M., Zhang, L. Y., & Shi, Y. F. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401034 · Cited by 341
Pinelo, M., Rubilar, M., Sineiro, J., & Núñez, M. J. (2004) · Food Chemistry · doi:10.1016/j.foodchem.2003.06.020 · Cited by 330
Raymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., & Levine, M. S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.052 · Cited by 325
Alvarez, A., Alarcón, R., Opazo, C., Campos, E. O., Muñoz, F. J., Calderón, F. H., Dajas, F., Gentry, M. K., Doctor, B. P., De Mello, F. G., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03213.1998 · Cited by 317
Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease
Bohnen, N. I., Muller, M. L. T. M., Kotagal, V., Koeppe, R. A., Kilbourn, M. A., Albin, R. L., & Frey, K. A. (2010) · Brain · doi:10.1093/brain/awq079 · Cited by 316
Vassar, R., & Citron, M. (2000) · Neuron · doi:10.1016/s0896-6273(00)00051-9 · Cited by 299
García-Ayllón, M.-S. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00022 · Cited by 299
Chen, X., Hu, Y., Cao, Z., Liu, Q., & Cheng, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02122 · Cited by 288
Liu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285
Bouayed, J., Rammal, H., Dicko, A., Younos, C., & Soulimani, R. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.06.028 · Cited by 277
Reading, P. J., Luce, A. K., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 272
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease
Goris, A., Williams‐Gray, C. H., Clark, G. R., Foltynie, T., Lewis, S. J. G., Brown, J., Ban, M., Spillantini, M. G., Compston, A., Burn, D. J., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21192 · Cited by 270
Combating oxidative stress disorders with citrus flavonoid: Naringenin
Zaidun, N. H., Thent, Z. C., & Latiff, A. A. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.017 · Cited by 265
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Wang, X., Li, P., Ding, Q., Wu, C., Zhang, W., & Tang, B. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11414 · Cited by 254
Kotagal, V., Albin, R. L., Müller, M. L. T. M., Koeppe, R. A., Chervin, R. D., Frey, K. A., & Bohnen, N. I. (2012) · Annals of Neurology · doi:10.1002/ana.22691 · Cited by 253
Rivastigmine for Alzheimer's disease
Birks, J. S., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub3 · Cited by 247
Ferrante, R. J., Kowall, N. W., Cipolloni, P. B., Storey, E., & Beal, M. F. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1006 · Cited by 244
Yang, G., Wang, Y., Tian, J., & Liu, J.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074916 · Cited by 241
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S., Walsh, S., Little, J. T., Behan, K., Reynolds, B., Ward, C., Jin, S., Thomas, R., Aisen, P. S., & Study, F. T. A. D. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318216eb7b · Cited by 240
Hsiao, H.-Y., Chen, Y.-C., Chen, H.-M., Tu, P.-H., & Chern, Y. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt036 · Cited by 239
Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease
Rochester, L., Yarnall, A. J., Baker, M. R., David, R. V., Lord, S., Galna, B., & Burn, D. J. (2012) · Brain · doi:10.1093/brain/aws207 · Cited by 227
Layer, P. G., Weikert, T., & Alber, R. (1993) · Cell & Tissue Research · doi:10.1007/bf00312823 · Cited by 221
Gait speed in Parkinson disease correlates with cholinergic degeneration
Bohnen, N. I., Frey, K. A., Studenski, S., Kotagal, V., Koeppe, R. A., Scott, P. J. H., Albin, R. L., & Müller, M. L. T. M. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a9f558 · Cited by 220
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
Aarsland, D., Hutchinson, M., & Larsen, J. P. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.949 · Cited by 219
Lou, H., Jing, X., Wei, X., Shi, H., Ren, D., & Zhang, X. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.026 · Cited by 212
Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease
Perez-Lloret, S., & Barrantes, F. J. (2016) · npj Parkinson's Disease · doi:10.1038/npjparkd.2016.1 · Cited by 210
Ishizawa, K., & Dickson, D. W. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.6.647 · Cited by 209
Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex
Rees, T. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00230-0 · Cited by 207
Adsersen, A., Gauguin, B., Gudiksen, L., & Jäger, A. K. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.09.032 · Cited by 205
Physiological functions of the cholinergic system in immune cells
Fujii, T., Mashimo, M., Moriwaki, Y., Misawa, H., Ono, S., Horiguchi, K., & Kawashima, K. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.05.002 · Cited by 204
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202
Devos, D., Moreau, C., Maltete, D., Lefaucheur, R., Kreisler, A., Eusebio, A., Defer, G., Ouk, T., Azulay, J.-P., Krystkowiak, P., et al. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306439 · Cited by 199
Apostolova, L. G. (2016) · Continuum · doi:10.1212/con.0000000000000307 · Cited by 198
Hesperetin Confers Neuroprotection by Regulating Nrf2/TLR4/NF-κB Signaling in an Aβ Mouse Model
Ikram, M., Muhammad, T., Rehman, S. U., Khan, A., Jo, M. G., Ali, T., & Kim, M. O. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1512-7 · Cited by 193
Loizzo, M. R., Tundis, R., Bonesi, M., Menichini, F., Luca, D. D., Colica, C., & Menichini, F. (2012) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.5708 · Cited by 192
Thalamic cholinergic innervation and postural sensory integration function in Parkinson’s disease
Müller, M. L. T. M., Albin, R. L., Kotagal, V., Koeppe, R. A., Scott, P. J. H., Frey, K. A., & Bohnen, N. I. (2013) · Brain · doi:10.1093/brain/awt247 · Cited by 190
Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Dulawa, S. C., & Janowsky, D. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0219-x · Cited by 187
Farlow, M. R., Salloway, S., Tariot, P. N., Yardley, J., Moline, M. L., Wang, Q., Brand-Schieber, E., Zou, H., Hsu, T., & Satlin, A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.019 · Cited by 186
Ghofrani, S., Joghataei, M.-T., Mohseni, S., Baluchnejadmojarad, T., Bagheri, M., Khamse, S., & Roghani, M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.001 · Cited by 185
Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia
Bohnen, N. I., Müller, M. L. T. M., Kotagal, V., Koeppe, R. A., Kilbourn, M. R., Gilman, S., Albin, R. L., & Frey, K. A. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.60 · Cited by 185
Acetylcholinesterase Involvement in Apoptosis
Zhang, X.-J., & Greenberg, D. S. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00040 · Cited by 183
Tamilselvam, K., Braidy, N., Manivasagam, T., Essa, M. M., Prasad, N. R., Karthikeyan, S., Thenmozhi, A. J., Selvaraju, S., & Guillemin, G. J. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/102741 · Cited by 182
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · cited 2×
“This is why the term Multi-Target Directed Ligand (MTDL) was coined [374,375].”
BackgroundVirtues and woes of AChE alternative splicing in stress-related neuropathologies
Meshorer, E., & Soreq, H. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.02.005 · Cited by 175
Oxidative Stress in Parkinson’s Disease: Potential Benefits of Antioxidant Supplementation
Percário, S., Barbosa, A. D. S., Varela, E. L. P., Gomes, A. R. Q., Ferreira, M. E. S., Moreira, T. D. N. A., & Dolabela, M. F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2360872 · Cited by 175
Justin Thenmozhi, A., William Raja, T. R., Manivasagam, T., Janakiraman, U., & Essa, M. M. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2016.1144846 · Cited by 174
Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking
Vazquez, J., & Baghdoyan, H. A. (2001) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2001.280.2.r598 · Cited by 173
Mundiñano, I.-C., Caballero, M.-C., Ordóñez, C., Hernandez, M., DiCaudo, C., Marcilla, I., Erro, M.-E., Tuñon, M.-T., & Luquin, M.-R. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0830-2 · Cited by 173
Reynolds, C. F., Butters, M. A., Lopez, O., Pollock, B. G., Dew, M. A., Mulsant, B. H., Lenze, E. J., Holm, M., Rogers, J. C., Mazumdar, S., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.184 · Cited by 171
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
Bohnen, N. I., Albin, R. L., Müller, M. L. T. M., Petrou, M., Kotagal, V., Koeppe, R. A., Scott, P. J. H., & Frey, K. A. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2757 · Cited by 167
Depression and sleep: pathophysiology and treatment
Thase, M. E. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/mthase · Cited by 166
Khan, M. B., Khan, M. M., Khan, A., Ahmed, M. E., Ishrat, T., Tabassum, R., Vaibhav, K., Ahmad, A., & Islam, F. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.07.025 · Cited by 165
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Blasco, H., Mavel, S., Corcia, P., & Gordon, P. H. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140916120118 · Cited by 164
A review of clinical treatment considerations of donepezil in severe Alzheimer's disease
Adlimoghaddam, A., Neuendorff, M., Roy, B., & Albensi, B. C. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13035 · Cited by 164
Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior
Warner-Schmidt, J. L., Schmidt, E. F., Marshall, J. J., Rubin, A. J., Arango-Lievano, M., Kaplitt, M. G., Ibañez-Tallon, I., Heintz, N., & Greengard, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209293109 · Cited by 163 · cited 1×
“These interneurons are also the main source of ACh in the nucleus accumbens [183,184].”
BackgroundRandomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan, I., Phipps, M., Pharr, V. L., Hallett, M., Grafman, J., & Salazar, A. (2001) · Neurology · doi:10.1212/wnl.57.3.467 · Cited by 163
Burns, A. S., Bernabei, R., Bullock, R. A., Cruz-Jentoft, A. J., Frölich, L., Höck, C., Raivio, M., Triau, E., Vandewoude, M. F. J., Wimo, A. B., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70261-8 · Cited by 162
Antunes, M. S., Goes, A. T. R., Boeira, S. P., Prigol, M., & Jesse, C. R. (2014) · Nutrition · doi:10.1016/j.nut.2014.03.024 · Cited by 161
Functional Characteristics of the Oxyanion Hole in Human Acetylcholinesterase
Ordentlich, A., Barak, D., Kronman, C., Ariel, N., Segall, Y., Velan, B., & Shafferman, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.31.19509 · Cited by 161
Sul, D., Kim, H.-S., Lee, D., Joo, S. S., Hwang, K. W., & Park, S. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.12.001 · Cited by 159
Benefits of rivastigmine on attention in dementia associated with Parkinson disease
Wesnes, K. A., McKeith, I., Edgar, C., Emre, M., & Lane, R. (2005) · Neurology · doi:10.1212/01.wnl.0000184517.69816.e9 · Cited by 159
Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease
Curry, D. W., Stutz, B., Andrews, Z. B., & Elsworth, J. D. (2018) · Journal of Parkinson's Disease · doi:10.3233/jpd-171296 · Cited by 159
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease
Dubois, B., Marie Chupin, A., Hampel, H. J., Lista, S., Cavedo, E., Croisile, B., Louis-Tisserand, G., Touchon, J., Bonafé, A., Ousset, P., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.10.003 · Cited by 156
Imaging microglial activation in Huntington's disease
Tai, Y., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. P. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.10.029 · Cited by 155
Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease
Rinne, J. O., Kaasinen, V., Järvenpää, T., Någren, K., Roivainen, A., Yu, M., Oikonen, V., & Kurki, T. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.1.113 · Cited by 154
Cholinergic neuronal defect without cell loss in Huntington's disease
Smith, R. A., Chung, H., Rundquist, S., Maat–Schieman, M. L. C., Colgan, L. A., Englund, E. M., Liu, Y.-J., Roos, R. A. C., Faull, R. L. M., Brundin, P., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl252 · Cited by 150
Zhang, J., Xie, X., Tang, M., Zhang, J., Zhang, B., Zhao, Q., Han, Y., Yan, W., Peng, C., & You, Z. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.012 · Cited by 150
Acetylcholinesterase-Aβ Complexes Are More Toxic than Aβ Fibrils in Rat Hippocampus
Reyes, A. E., Chacón, M. A., Dinamarca, M. C., Cerpa, W. F., Morgan, C., & Inestrosa, N. C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63774-1 · Cited by 148
Robertson, R. T. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90531-3 · Cited by 147
Bohnen, N. I., Kaufer, D., Hendrickson, R., Constantine, G. M., Mathis, C. A., & Moore, R. Y. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100073 · Cited by 146
Kennedy, D. O., Pace, S. M., Haskell‐Ramsay, C. F., Okello, E. J., Milne, A., & Scholey, A. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300907 · Cited by 145
Kumar, P., & Kumar, A. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.08.028 · Cited by 145
Litvinenko, I., Odinak, M. M., Mogil'naia, V. I., & Emelin, А. Y. (2008) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-008-9077-3 · Cited by 144
Bhattacharya, S., Haertel, C., Maelicke, A., & Montag, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089454 · Cited by 142 · cited 1×
“Mice treated with galantamine demonstrated, besides benefits for cognitive impairment, reduced levels of βA in the brain and decreased glial cell activation [290].”
BackgroundAcetylcholinesterase Plays a Pivotal Role in Apoptosome Formation
Park, S.-E., Kim, N. D., & Yoo, Y. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0649 · Cited by 142
Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease
Geula, C., & Mesulam, M. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)90419-8 · Cited by 140
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis
Krupp, L., Christodoulou, C., Melville, P., SCHERL, W. F., Pai, L.-Y., Muenz, L. R., He, D., Benedict, R. H. B., Goodman, A. D., Rizvi, S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318218107a · Cited by 139
The cholinergic system and depression
Dagytė, G., den Boer, J. A., & Trentani, A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.023 · Cited by 138
Sternfeld, M., Shoham, S., Klein, O., Flores‐Flores, C., Evron, T., Idelson, G. H., Kitsberg, D., Patrick, J. W., & Soreq, H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.140004597 · Cited by 138
Kim, H., Kang, C., Jayasooriya, R. G. P. T., Dilshara, M. G., Lee, S., Choi, Y. H., Seo, Y. T., & Kim, G. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.03.022 · Cited by 137
Nizri, E., Irony-Tur-Sinai, M., Faranesh, N., Lavon, I., Lavi, E., Weinstock, M., & Brenner, T. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.018 · Cited by 137
Lahiri, D. K., Chen, D., Maloney, B., Holloway, H. W., Yu, Q.-S., Utsuki, T., Giordano, T., Sambamurti, K., & Greig, N. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112102 · Cited by 137
Justin‐Thenmozhi, A., Bharathi, M. D., Kiruthika, R., Manivasagam, T., Borah, A., & Essa, M. M. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9904-4 · Cited by 137
Cummings, J. L., Lai, T., Hemrungrojn, S., Mohandas, E., Kim, S., Nair, G., & Dash, A. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12484 · Cited by 136
Haider, S., Liaquat, L., Ahmad, S., Batool, Z., Siddiqui, R. A., Tabassum, S., Shahzad, S., Rafiq, S., & Naz, N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227631 · Cited by 136
Tsuboi, Y., Wszołek, Z. K., Graff‐Radford, N. R., Cookson, N., & Dickson, D. W. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00453.x · Cited by 135
Clinical Pharmacokinetics of Galantamine
Farlow, M. R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00005 · Cited by 134
Md, S., Gan, S. Y., Haw, Y. H., Ho, C. L., Wong, S., & Choudhury, H. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.06.190 · Cited by 134
Sigma receptors: Potential targets for a new class of antidepressant drug
Fishback, J. A., Robson, M. J., Xu, Y., & Matsumoto, R. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.003 · Cited by 133
Abnormal Motor Cortex Excitability in Preclinical and Very Early Huntington's Disease
Schippling, S., Schneider, S. A., Bhatia, K., Münchau, A. M., Rothwell, J. C., Tabrizi, S. J., & Orth, M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.026 · Cited by 133
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
Kadir, A., Andreasen, N., Almkvist, O., Wall, A. E., Forsberg, A., Engler, H., Hagman, G., Lärksäter, M., Winblad, B. G., Zetterberg, H., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21345 · Cited by 132
Heo, H. J., Kim, M., Lee, J., Choi, S. J., Cho, H., Hong, B.-S., Kim, H. K., Kim, E., & Shin, D.-H. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000076349 · Cited by 131
Donato, F., de Gomes, M. G., Goes, A. T. R., Filho, C. B., Fabbro, L. D., Antunes, M. S., Souza, L. C., Boeira, S. P., & Jessé, C. R. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.03.004 · Cited by 131
Koh, J., & Choi, D. W. (1988) · Brain Research · doi:10.1016/0006-8993(88)90897-9 · Cited by 131
Morin attenuates tau hyperphosphorylation by inhibiting GSK3β
Gong, E. J., Park, H. R., Kim, M. E., Piao, S., Lee, E., Jo, D., Chung, H. Y., Ha, N., Mattson, M. P., & Lee, J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.005 · Cited by 129
dos Santos, D. M., Milatović, D., Andrade, V., Batoréu, M. C. C., Aschner, M., & dos Santos, A. P. M. (2011) · Toxicology · doi:10.1016/j.tox.2011.11.017 · Cited by 128
Progressive supranuclear palsy: Advances in diagnosis and management
Coughlin, D. G., & Litvan, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.014 · Cited by 126
Yi, L., Li, C., Zhan, X., Cui, C.-C., Xiao, F., Zhou, L.-P., & Xie, Y. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.024 · Cited by 125
Pedraza‐Chaverrí, J., Reyes-Fermín, L. M., Nolasco-Amaya, E. G., Orozco‐Ibarra, M., Medina‐Campos, O. N., González-Cuahutencos, O., Rivero‐Cruz, I., & Mata, R. (2008) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.11.002 · Cited by 125
Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo
Zhang, Z., Cao, X., Xiong, N., Wang, H., Huang, J., Sun, S., & Wang, T. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.77 · Cited by 124
Galantamine for Alzheimer's disease
Prvulovic, D., Hampel, H. J., & Pantel, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003592137 · Cited by 124
Kennedy, D. O., Dodd, F. L., Robertson, B. C., Okello, E. J., Reay, J. L., Scholey, A. B., & Haskell, C. F. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110385594 · Cited by 123
The catecholaminergic–cholinergic balance hypothesis of bipolar disorder revisited
van Enkhuizen, J., Janowsky, D. S., Olivier, B., Minassian, A., Perry, W., Young, J. W., & Geyer, M. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.05.063 · Cited by 123
Functional redundancy of acetylcholinesterase and neuroligin in mammalian neuritogenesis
Grifman, M., Galyam, N., Seidman, S., & Soreq, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13935 · Cited by 123
Jangra, A., Lukhi, M. M., Sulakhiya, K., Baruah, C. C., & Lahkar, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.031 · Cited by 122 · cited 1×
“Mangiferin pretreatment reduced anxiety-like behavior and LPS-induced anhedonic behavior in mice [547].”
BackgroundSymptomatic Treatment of Huntington Disease
Adam, O. R., & Jankovic, J. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.008 · Cited by 122
Lee, Y. W., Kim, D. H., Jeon, S. J., Park, S. J., Kim, J. M., Jung, J. M., Lee, H. E., Bae, S. G., Oh, H. K., Son, K. H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.015 · Cited by 122
Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway
Frandsen, J. R., & Narayanasamy, P. (2017) · Redox Biology · doi:10.1016/j.redox.2017.10.015 · Cited by 122
From Natural Products to New Synthetic Small Molecules: A Journey through the World of Xanthones
Pinto, M. M. M., Palmeira, A., Fernandes, C., Resende, D. I. S. P., Sousa, E., Cidade, H. M., Tiritan, M. E., Correia‐da‐Silva, M., & Cravo, S. M. M. (2021) · Molecules · doi:10.3390/molecules26020431 · Cited by 121
Rahigude, A., Bhutada, P., Kaulaskar, S., Aswar, M. K., & Otari, K. V. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.026 · Cited by 119
Tundis, R., Loizzo, M. R., Bonesi, M., Menichini, F., Mastellone, V., Colica, C., & Menichini, F. (2012) · Journal of Food Science · doi:10.1111/j.1750-3841.2011.02511.x · Cited by 119
Wang, D., Liu, L., Zhu, X., Wu, W., & Wang, Y. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0098-x · Cited by 117
Huperzine A in the Treatment of Alzheimer′s Disease and Vascular Dementia: A Meta‐Analysis
Xing, S.-H., Zhu, C., Zhang, R., & An, L. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/363985 · Cited by 117
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Pilotto, A., Franceschi, M., D’Onofrio, G., Bizzarro, A., Mangialasche, F., Cascavilla, L., Paris, F., Matera, M. G., Pilotto, A., Daniele, A., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bbe3 · Cited by 117
Effects of donepezil on memory and cognition in multiple sclerosis
Christodoulou, C., Melville, P., SCHERL, W. F., MacAllister, W. S., Elkins, L. E., & Krupp, L. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.08.021 · Cited by 115
Olugbemide, A. S., Ben‐Azu, B., Bakre, A. G., Ajayi, A. M., Femi-Akinlosotu, O. M., & Umukoro, S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.003 · Cited by 114
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis
Wiebenga, O. T., Heilman, K. M., Krupp, L. B., Hulst, H. E., Kooi, E.-J., Killestein, J., Geurts, J. J. G., Williamson, J. B., Christodoulou, C., & Benedict, R. H. B. (2011) · Neurology · doi:10.1212/wnl.0b013e318239c242 · Cited by 112
Cholinergic and dopaminergic mechanisms in Huntington's chorea
Aquilonius, S., & Sjöström, R. (1971) · Life Sciences · doi:10.1016/0024-3205(71)90146-9 · Cited by 111
HCN2 Channels in Cholinergic Interneurons of Nucleus Accumbens Shell Regulate Depressive Behaviors
Cheng, J., Umschweif, G., Leung, J., Sagi, Y., & Greengard, P. (2019) · Neuron · doi:10.1016/j.neuron.2018.12.018 · Cited by 110
β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia
Müller, M. L. T. M., Frey, K. A., Petrou, M., Kotagal, V., Koeppe, R. A., Albin, R. L., & Bohnen, N. I. (2012) · Movement Disorders · doi:10.1002/mds.25213 · Cited by 110
Humoral factors in ALS patients during disease progression
Ehrhart, J. C., Smith, A. J., Kuzmin‐Nichols, N., Zesiewicz, T., Jahan, I., Shytle, R. D., Kim, S.-H., Sanberg, C. D., Vu, T., Gooch, C. L., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0350-4 · Cited by 109
Souza, L. C., de Gomes, M. G., Goes, A. T. R., Fabbro, L. D., Filho, C. B., Boeira, S. P., & Jessé, C. R. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.09.003 · Cited by 108
Menze, E. T., Tadros, M. G., Abdel-Tawab, A. M., & Khalifa, A. E. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.07.007 · Cited by 107
N-Acetylcholinesterase-Induced Apoptosis in Alzheimer's Disease
Toiber, D., Berson, A., Greenberg, D., Melamed‐Book, N., Diamant, S., & Soreq, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003108 · Cited by 107
McAllister, T. W., ZAFONTE, R. D., Jain, S., Flashman, L. A., George, M. S., Grant, G. A., He, F., Lohr, J. B., Andaluz, N. O., Summerall, L., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.282 · Cited by 107
Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer’s Disease?
Qian, Z., & Ke, Y. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00216 · Cited by 106
Alberdi, E. M., Sánchez‐Gómez, M. V., Ruiz, A., Cavaliere, F., Ortiz-Sanz, C., Quintela‐López, T., Capetillo‐Zarate, E., Solé‐Domènech, S., & Matute, C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2856063 · Cited by 106
Jo, S. H., Kim, M. E., Cho, J. H., Lee, Y., Lee, J., Park, Y., & Lee, J. S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01174-5 · Cited by 106
Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP/PS1 mice
Li, C., Zug, C., Qu, H., Schluesener, H. J., & Zhang, Z. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.12.012 · Cited by 104
Huang, S., Tsai, S.-Y., Lin, J., Wu, C., & Yen, G. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100682 · Cited by 102
Marutle, A., Ohmitsu, M., Nilbratt, M., Greig, N. H., Nordberg, A. K., & Sugaya, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705346104 · Cited by 102
Maccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 102
Machado, D. G., Cunha, M. P., Neis, V. B., Balen, G. O., Colla, A. R. D. S., Grando, J., Brocardo, P. S., Bettio, L. E. B., Capra, J. C., & Rodrigues, A. L. S. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.024 · Cited by 98
Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity
Müller, T. C., da Rocha, J. B. T., Morsch, V. M., Neis, R. T., & Schetinger, M. R. C. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00071-6 · Cited by 98
Sunanda, Rao, B. S. S., & Raju, T. R. (2000) · Neurochemical Research · doi:10.1023/a:1026606201069 · Cited by 97
BenMoyal‐Segal, L., Vander, T., Shifman, S., Bryk, B., Ebstein, R. P., Marcus, E., Stessman, J., Darvasi, A., Herishanu, Y. O., Friedman, A., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2106fje · Cited by 96
Cornejo, A., Sandoval, F. A. A., Caballero, L., Machuca, L., Muñoz, P., Caballero, J., Perry, G. L., Ardiles, A., Areche, C., & Melo, F. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1347783 · Cited by 96
Manganese, Copper, and Zinc in Cerebrospinal Fluid from Patients with Multiple Sclerosis
Melø, T. M., Larsen, C. B., White, L. R., Aasly, J. O., Sjøbakk, T. E., Flaten, T. P., Sonnewald, U., & Syversen, T. L. M. (2003) · Biological Trace Element Research · doi:10.1385/bter:93:1-3:1 · Cited by 95
Sharma, K. V., Koenigsberger, C., Brimijoin, S., & Bigbee, J. W. (2001) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20010115)63:2<165::aid-jnr1008>3.0.co;2-o · Cited by 95
Acetylcholinesterase in cell adhesion, neurite growth and network formation
Sperling, L. E., & Layer, P. G. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06237.x · Cited by 94
Evaluation of Rivastigmine in Alzheimer’s Disease
Nguyen, K. T., Hoffman, H. L., Chakkamparambil, B., & Grossberg, G. T. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0052 · Cited by 94
Effect of donepezil on motor and cognitive function in Huntington disease
Cubo, E., Shannon, K. M., Tracy, D. K., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000238106.10423.00 · Cited by 93
New insights into huperzine A for the treatment of Alzheimer's disease
Zhang, H. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.128 · Cited by 92
Cholinergic systems in progressive supranuclear palsy
Warren, N. (2004) · Brain · doi:10.1093/brain/awh391 · Cited by 92
Islam, N. U., Amin, R., Shahid, M. M., Amin, M. U., Zaib, S., & Iqbal, J. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1791-3 · Cited by 92
Kavitha, M., Nataraj, J., Essa, M. M., Memon, M. A., & Manivasagam, T. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.09.016 · Cited by 91 · cited 1×
“In addition, mangiferin was also shown to have beneficial effects in mice with PD [544].”
BackgroundRivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0709-x · Cited by 91
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years
Small, G. W., Kaufer, D., Mendiondo, M. S., Quarg, P., & Spiegel, R. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00524.x · Cited by 91
JIANG, P., Li, C., Xiang, Z., & Jiao, B. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2254 · Cited by 91
Gerber, Y. N., Sabourin, J.-C., Rábano, M., Vivanco, M. D., & Perrin, F. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036000 · Cited by 91
Chen, C., Wei, Y.-Z., He, X., Li, D., Wang, G., Li, J.-J., & Zhang, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00936 · Cited by 91
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 91
Cited by
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Shehata, M. K., Ismail, A. A., & Kamel, M. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s417928 · Cited by 55
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
“140 These enzymes are critically involved in inflammation regulation, phagocytosis, autophagy, and pathological protein degradation, making them ideal “pathological microenvironmental triggers” for designing enzyme-responsive delivery systems.”
Metal Nanoparticles in Alzheimer’s Disease
Behera, A., Sa, N., Pradhan, S. P., Swain, S., & Sahu, P. K. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-220112 · Cited by 50
Metadata
- Authors
- Walczak-Nowicka, Ł. J., & Herbet, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-27
- Volume
- 22
- Issue
- 17
- Pages
- 9290
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3197674566
- Cited by
- 335
- References
- 512
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.